Bryce Point Capital LLC Buys Shares of 44,063 Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Bryce Point Capital LLC purchased a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 44,063 shares of the company's stock, valued at approximately $845,000. Bryce Point Capital LLC owned 0.06% of Viridian Therapeutics as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. R Squared Ltd purchased a new stake in Viridian Therapeutics during the 4th quarter worth about $26,000. AlphaQuest LLC lifted its stake in Viridian Therapeutics by 119.0% in the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock worth $54,000 after acquiring an additional 1,519 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Viridian Therapeutics by 17.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,997 shares of the company's stock worth $318,000 after acquiring an additional 2,036 shares during the last quarter. Arizona State Retirement System increased its position in shares of Viridian Therapeutics by 19.5% in the 4th quarter. Arizona State Retirement System now owns 16,596 shares of the company's stock valued at $318,000 after purchasing an additional 2,708 shares during the last quarter. Finally, Corebridge Financial Inc. raised its holdings in shares of Viridian Therapeutics by 8.6% in the 4th quarter. Corebridge Financial Inc. now owns 36,336 shares of the company's stock valued at $697,000 after purchasing an additional 2,878 shares in the last quarter.

Viridian Therapeutics Price Performance

NASDAQ:VRDN traded down $0.17 during mid-day trading on Tuesday, hitting $11.61. 285,831 shares of the company's stock traded hands, compared to its average volume of 1,178,780. The firm's 50 day simple moving average is $16.04 and its 200 day simple moving average is $19.33. The company has a market cap of $946.04 million, a PE ratio of -2.71 and a beta of 0.81. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. Viridian Therapeutics, Inc. has a 1 year low of $10.88 and a 1 year high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.24. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The company had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.05 million. Sell-side analysts expect that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Wells Fargo & Company reissued an "equal weight" rating and issued a $27.00 target price (down previously from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Needham & Company LLC reiterated a "buy" rating and issued a $38.00 target price on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. HC Wainwright restated a "buy" rating and set a $34.00 price target on shares of Viridian Therapeutics in a research note on Monday, December 16th. Finally, Royal Bank of Canada increased their price target on Viridian Therapeutics from $44.00 to $47.00 and gave the stock an "outperform" rating in a report on Tuesday, December 17th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $35.70.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.